Literature DB >> 8487570

Indications, risks, and results of completion pneumonectomy.

J Grégoire1, J Deslauriers, L Guojin, J Rouleau.   

Abstract

Completion pneumonectomy refers to an operation intended to remove what is left of a lung partially resected during a previous operation. The procedure is seldom indicated and, according to current medical literature, it carries a higher risk of operative mortality and morbidity than does standard pneumonectomy, especially when done for benign disease. Over the past 20 years, 60 consecutive patients aged 17 to 70 years and having a diagnosis of recurrent lung cancer (n = 28), new primary lung cancer (n = 13), or benign pleuropulmonary disease (n = 19) underwent completion pneumonectomy. The mean interval between the first operation and completion pneumonectomy was 30 months for patients with carcinoma and 215 months for patients with benign disease. For all patients, the previous thoracotomy incision was reopened and maneuvers such as rib resection, intrapericardial blood vessel ligation, division of the bronchus first, local application of glues and hemostatic agents, and bronchial reinforcement were routinely used. Six patients died during (n = 2) or after (n = 4) the operation, for an overall operative mortality of 10%. The rate was higher for patients with carcinoma (11.6%) than for patients with benign disease (5.9%). Actuarial 5-year survivals from the time of completion pneumonectomy were 48% for the entire population, 33% for patients with cancer, and 88% for patients with benign disease. These results suggest that completion pneumonectomy can be done with an operative risk similar to the one reported for standard pneumonectomy (6% to 10%). In addition, patients undergoing completion pneumonectomy have a reasonable prospect for long-term survival.

Entities:  

Mesh:

Year:  1993        PMID: 8487570

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

1.  Completion pneumonectomy for recurrent or second primary lung cancer.

Authors:  M Muraoka; T Oka; T Takahashi; S Akamine; M Morinaga; T Nagayasu; Y Tagawa; H Ayabe
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-07

2.  Surgical resection of recurrent lung cancer in patients following curative resection.

Authors:  Hyoung Soo Kim; Hoseok I; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Jhingook Kim
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

3.  [Completion pneumonectomy. Indications and results].

Authors:  W Jungraithmayr; J Hasse; M Olschewski; E Stoelben
Journal:  Chirurg       Date:  2005-02       Impact factor: 0.955

4.  Laparoscopic cholecystectomy in a patient with previous pneumonectomy: a case report and discussion of anaesthetic considerations.

Authors:  Dash Faith Newington; Sanaa Ismail
Journal:  Case Rep Anesthesiol       Date:  2014-11-09

5.  Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries.

Authors:  Dragan Subotic; Laureano Molins; Ivan Soldatovic; Dejan Moskovljevic; Lucia Collado; Jorge Hernández
Journal:  World J Surg Oncol       Date:  2018-05-28       Impact factor: 2.754

6.  Completion Pneumonectomy for Non-Small-Cell Lung Cancer: Does Induction Treatment Influence Postoperative Outcomes?

Authors:  Domenico Galetta; Lorenzo Spaggiari
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575

7.  Completion pneumonectomy: Indications and outcomes in non-small cell lung cancer.

Authors:  Serkan Yazgan; Ahmet Üçvet; Soner Gürsoy; Özgür Samancılar
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-09-16       Impact factor: 0.332

8.  Completion pneumonectomy for lung cancer treatment: early and long term outcomes.

Authors:  Peng Zhang; Chao Jiang; Wenxin He; Nan Song; Xiao Zhou; Gening Jiang
Journal:  J Cardiothorac Surg       Date:  2012-10-09       Impact factor: 1.637

9.  Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer.

Authors:  Abby White; Suden Kucukak; Daniel N Lee; Raphael Bueno; Michael Jaklitsch; Steven Mentzer; David Sugarbaker; Jon Wee; Scott J Swanson
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.